AB0756 GUSELKUMAB IMPROVED WORK PRODUCTIVITY AND DAILY ACTIVITY IN PATIENTS WITH PSORIATIC ARTHRITIS: RESULTS FROM A PHASE 3 TRIAL
Authors: J. Curtis, I. Mcinnes, P. Rahman, W. Tillett, P. J. Mease, A. Kollmeier, E. C. Hsia, B. Zhou, P. Agarwal, S. Peterson, C. Han
Journal: Annals of the Rheumatic Diseases (2020)

Background: DISCOVER 2 (DISC 2) is a Phase 3 trial of anti-IL-23-specific mAb guselkumab (GUS) in psoriatic arthritis (PsA) pts, who experience impaired physical function, resulting in disability, work productivity loss, and economic consequences. 1 Objectives: To evaluate the effect of GUS on impaired work productivity and daily activity in DISC 2 using the Work Productivity and Activity Impairment Questionnaire: Psoriatic Arthritis (WPAI-PsA). Methods: Bio-naïve adults with active PsA despite nonbiologic DMARDs &amp;/or NSAIDs received subcutaneous GUS 100 mg every (q) 4 weeks (W); GUS 100 mg W0, W4, q8W; or placebo (PBO). WPAI-PsA assesses, due to PsA over the previous week, work time missed (absenteeism), impairment while working (presenteeism), and impaired overall work productivity (absenteeism + presenteeism) and daily activity. Percentage change from baseline was analyzed for WPAI-PsA domains using mixed-effect model repeated measure (MMRM). Indirect savings from improved overall work productivity were estimated with 2018 US mean yearly wage estimate (all occupations). 2 Results: At Week 24, impaired overall work productivity and daily activity were improved 20-22% in GUS-treated and 10-11% in PBO-treated pts (Table). Potential yearly indirect savings from improved overall work productivity was $10,242 with GUS q8W and $10,404 with GUS q4W vs $5,648 with PBO; $4,594 and $4,756 difference, respectively. Conclusion: Improvement in overall work productivity and daily activity was greater with GUS versus PBO among pts with moderate-to-severe PsA, resulting in potential annual incremental economic gains. References: [1]Tillett W et al. Rheumatol (Oxford). 2012;51:275–283. [2]US Bureau of Labor Statistics. May 2018 National Occupational Employment and Wage Estimates United States. https://www.bls.gov/oes/current/oes_nat.htm#00-000 Table. Model-based estimates of mean change from baseline in WPAI-PsA domains % change from baseline PBO GUS 100 mg q8W GUS 100 mg q4W W16 W24 W16 W24 W16 W24 Work time missed (absenteeism), n 155 152 141 145 145 143 LSMean -4.6 (-7.2, -1.9) -3.5 (-6.4, -0.6) -3.5 (-6.2, -0.7) -3.1 (-6.1, -0.1) -4.7 (-7.4, -2.0) -3.8 (-6.8, -0.8) LSMean diff 1.1 (-2.6, -4.8)* 0.4 (-3.7, 4.5)* -0.2 (-3.9, 3.5)* -0.3 (-4.4, 3.8)* Impairment while working (presenteeism), n 131 130 125 129 133 130 LSMean -10.3 (-13.9, -6.7) -10.2 (-13.7, -6.7) -16.1 (-19.7, -12.4) -19.4 (-22.9, -15.9) -15.1 (-18.7, -11.5) -19.5 (-23.0, -16.0) LSMean diff -5.8 (-10.8, -0.8)† -9.2 (-14.0, -4.4) ‡ -4.8 (-9.7, 0.1)* -9.3 (-14.1, -4.5) ‡ Overall work productivity impairment (absenteeism + presenteeism), n 131 130 125 129 133 130 LSMean -11.2 (-15.0, -7.5) -10.9 (-14.6, -7.1) -15.9 (-19.7, -12.2) -19.7 (-23.4, -16.0) -15.8 (-19.5, -12.1) -20.0 (-23.7, -16.3) LSMean diff -4.7 (-9.9, 0.5)* -8.8 (-14.0, -3.7) ‡ -4.6 (-9.7, 0.5)* -9.2 (-14.3, -4.0) ‡ Daily activity impairment, n 244 244 247 246 243 245 LSMean -10.6 (-13.3, -7.9) -10.3 (-13.1, -7.6) -17.1 (-19.8, -14.4) -21.5 (-24.2, -18.7) -17.0 (-19.7, -14.3) -20.5 (-23.2, -17.7) LSMean diff -6.5 (-10.2, -2.8) ‡ -11.1 (-15.0, -7.4) ‡ -6.5 (-10.2, -2.7) ‡ -10.2 (-14.0, -6.4) ‡ Data are % (95% CI) *p&gt;0.05, †p&lt;0.05, ‡ p&lt;0.001 LSmeans, p values based on MMRM LSmean diffs, p values vs PBO Acknowledgments: None Disclosure of Interests: Jeffrey Curtis Grant/research support from: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Consultant of: AbbVie, Amgen, Bristol-Myers Squibb, Corrona, Janssen, Lilly, Myriad, Pfizer, Regeneron, Roche, UCB, Iain McInnes Grant/research support from: Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Janssen, and UCB, Consultant of: AbbVie, Bristol-Myers Squibb, Celgene, Eli Lilly and Company, Gilead, Janssen, Novartis, Pfizer, and UCB, Proton Rahman Grant/research support from: Janssen and Novartis, Consultant of: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, and Pfizer., Speakers bureau: Abbott, AbbVie, Amgen, BMS, Celgene, Lilly, Janssen, Novartis, Pfizer, William Tillett Grant/research support from: AbbVie, Celgene, Eli Lilly, Janssen, Novartis, Pfizer Inc, UCB, Consultant of: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, MSD, Pfizer Inc, UCB, Speakers bureau: AbbVie, Amgen, Celgene, Lilly, Janssen, Novartis, Pfizer Inc, UCB, Philip J Mease Grant/research support from: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – grant/research support, Consultant of: Abbott, Amgen, Biogen Idec, BMS, Celgene Corporation, Eli Lilly, Novartis, Pfizer, Sun Pharmaceutical, UCB – consultant, Speakers bureau: Abbott, Amgen, Biogen Idec, BMS, Eli Lilly, Genentech, Janssen, Pfizer, UCB – speakers bureau, Alexa Kollmeier Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Research &amp; Development, LLC, Elizabeth C Hsia Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Research &amp; Development, LLC, Bei Zhou Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Research &amp; Development, LLC, Prasheen Agarwal Shareholder of: Johnson &amp; Johnson, Employee of: Janssen Research &amp; Development, LLC, Steve Peterson Employee of: Janssen Research &amp; Development, LLC, Chenglong Han Employee of: Janssen Research &amp; Development, LLC